1 Ocak 2019 Dergi makalesi Açık Erişim

Farzani, Touraj Aligholipour; Foldes, Katalin; Hanifehnezhad, Alireza; Ilce, Burcu Yener; Dagalp, Seval Bilge; Khiabani, Neda Amirzadeh; Erguenay, Koray; Alkan, Feray; Karaoglu, Taner; Bodur, Hurrem; Ozkul, Aykut

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Foldes, Katalin</subfield>
    <subfield code="u">Ankara Univ, Virol Dept, Fac Vet Med, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Hanifehnezhad, Alireza</subfield>
    <subfield code="u">Ankara Univ, Virol Dept, Fac Vet Med, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ilce, Burcu Yener</subfield>
    <subfield code="u">Ankara Univ, Biotechnol Inst, TR-06560 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Dagalp, Seval Bilge</subfield>
    <subfield code="u">Ankara Univ, Virol Dept, Fac Vet Med, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Khiabani, Neda Amirzadeh</subfield>
    <subfield code="u">Ankara Univ, Biotechnol Inst, TR-06560 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Erguenay, Koray</subfield>
    <subfield code="u">Hacettepe Univ, Dept Med Microbiol, Virol Unit, Fac Med, TR-06100 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Alkan, Feray</subfield>
    <subfield code="u">Ankara Univ, Virol Dept, Fac Vet Med, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Karaoglu, Taner</subfield>
    <subfield code="u">Ankara Univ, Virol Dept, Fac Vet Med, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Bodur, Hurrem</subfield>
    <subfield code="u">Saglik Bilimleri Univ, Numune Training &amp; Res Hosp, Infect Dis Clin, TR-06100 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ozkul, Aykut</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="p">VIRUSES-BASEL</subfield>
    <subfield code="v">11</subfield>
    <subfield code="n">3</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.3390/v11030237</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFN alpha/beta/gamma R-/- Mice Models</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Farzani, Touraj Aligholipour</subfield>
    <subfield code="u">Ankara Univ, Virol Dept, Fac Vet Med, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:zenodo.org:71641</subfield>
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="2">opendefinition.org</subfield>
    <subfield code="a">cc-by</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2019-01-01</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/71641/files/bib-28100bf5-9e5b-4681-bbb4-e073de954a1d.txt</subfield>
    <subfield code="z">md5:2f51262639c3e46fd1fc3f4256f1b743</subfield>
    <subfield code="s">391</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <controlfield tag="005">20210316033155.0</controlfield>
  <controlfield tag="001">71641</controlfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Crimean-Congo hemorrhagic fever virus (CCHFV) is the causative agent of a tick-borne infection with a significant mortality rate of up to 40% in endemic areas, with evidence of geographical expansion. Due to a lack of effective therapeutics and control measures, the development of a protective CCHFV vaccine remains a crucial public health task. This paper describes, for the first time, a Bovine herpesvirus type 4 (BoHV-4)-based viral vector (BoHV4- increment TK-CCHFV-N) and its immunogenicity in BALB/c and protection potential in IFN alpha/beta/gamma R-/- mice models in comparison with two routinely used vaccine platforms, namely, Adenovirus type 5 and a DNA vector (pCDNA3.1 myc/His A), expressing the same antigen. All vaccine constructs successfully elicited significantly elevated cytokine levels and specific antibody responses in immunized BALB/c and IFN alpha/beta/gamma R-/- mice. However, despite highly specific antibody responses in both animal models, the antibodies produced were unable to neutralize the virus in vitro. In the challenge experiment, only the BoHV4- increment TK-CCHFV-N and Ad5-N constructs produced 100% protection against lethal doses of the CCHFV Ank-2 strain in IFN alpha/beta/gamma R-/- mice. The delivery platforms could not be compared due to similar protection rates in IFN alpha/beta/gamma R-/- mice. However, during the challenge experiment in the T cell and passive antibody transfer assay, BoHV4- increment TK-CCHFV-N was dominant, with a protection rate of 75% compared to others. In conclusion, vector-based CCHFV N protein expression constitutes an effective approach for vaccine development and BoHV-4 emerged as a strong alternative to previously used viral vectors.</subfield>
  </datafield>
</record>